Multiple Roles of PIKA Technology in the Cancer Immunity Cycle
Effective recognition and removal of cancer cells by the anticancer immune response involves a series of expected events. This sequence of events, which expands with each iteration, is referred to as the cancer-immunity cycle. Yisheng therapeutic candidate YS-ON-001 is able to induce the production of pro-inflammatory cytokines such as interferon alpha, which promote activation of antigen presenting cells (APCs) and enhance antigen presentation (see step 2). YS-ON-001 has demonstrated the ability to upregulate co-stimulatory molecules required for T cell priming and activation (see step 3) such as CD86. In addition, in animal models YS-ON-001 leads to increased infiltration of T cells and NK cells into tumors (see step 5).